Temporary Reimbursement Granted for Pediatric Smectite After Indication Removal

The removal of the pediatric indication for di‑octahedral smectite has raised concerns about billing confusion for frontline pharmacies. In response to a request from the Korean Pharmaceutical Association, a temporary three‑day reimbursement measure was introduced. The association’s president, Kwon Young‑hee, announced via a member alert on the 15th that the government agreed to recognize reimbursement for smectite preparations dispensed to patients under 19 years of age for three days, aiming to minimize financial losses for member pharmacies caused by the sudden regulatory change.